Kangtai Biological: Application for the market authorization of influenza virus split vaccine has been accepted.

Kangtai Biological announced that the company's research and development of influenza virus split vaccines recently obtained the "Acceptance Notice" issued by the National Medical Products Administration for market approval application. This vaccine is suitable for people aged 3 and above, can stimulate the body to produce immunity against influenza viruses, and is used to prevent epidemic influenza caused by vaccine-related strains of influenza viruses. Currently, there are many influenza vaccines on the market at home and abroad, including products from Changchun Biological Products Research Institute Co., Ltd., Hualan Biological Vaccines Co., Ltd., Beijing Kexing Bioproducts Co., Ltd., among other manufacturers. If this vaccine successfully obtains market approval, it will enrich the company's product layout, enhance core competitiveness, and improve market position.